The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Updates on targeted therapy in the treatment of myeloma
Lukas John, MD, University Hospital Heidelberg, Heidelberg, Germany, shares his insights into recent advances in precision therapy in multiple myeloma, drawing focus on BRAF inhibitors and Akt inhibitors. Dr John explains why there are difficulties with successful targeted therapy in myeloma, including the ability of tumors to develop resistance, the genetic heterogeneity of this disease, and emphasizes the need for further research to improve personalized treatment options for patients with multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
